Cosette Marie Wheeler

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. doi request reprint The natural history of cervical human papillomavirus infections and cervical cancer: gaps in knowledge and future horizons
    Cosette Marie Wheeler
    Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Obstet Gynecol Clin North Am 40:165-76. 2013
  2. doi request reprint Cervical histopathology variability among laboratories: a population-based statewide investigation
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services DHHS, Bethesda, MD, USA
    Am J Clin Pathol 139:330-5. 2013
  3. pmc A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination
    Cosette M Wheeler
    Department of Pathology and Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, Albuquerque, NM87131, USA
    Int J Cancer 132:198-207. 2013
  4. doi request reprint Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: r
    Cosette M Wheeler
    Department of Pathology, University of New Mexico, Health Science Center, Albuquerque, NM 87131, USA
    Pediatr Infect Dis J 30:e225-34. 2011
  5. doi request reprint Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    Cosette M Wheeler
    Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
    Lancet Oncol 13:100-10. 2012
  6. doi request reprint Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
    Cosette M Wheeler
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center School of Medicine, Albuquerque, NM 87131, USA
    Vaccine 26:686-96. 2008
  7. ncbi request reprint Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing
    Cosette M Wheeler
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, Building 191, 1816 Sigma Chi Road, Albuquerque, NM 87131, USA
    Nat Clin Pract Oncol 4:224-35. 2007
  8. ncbi request reprint EUROGIN 2007 roadmap--conclusion
    Cosette M Wheeler
    Department of Molecular Genetics, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, 1816 Sigma Chi Road NE, Albuquerque, NM 87131, USA
    Vaccine 26:A28-31. 2008
  9. ncbi request reprint Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer
    Cosette M Wheeler
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, School of Medicine, Albuquerque, NM 87131, USA
    J Infect Dis 194:1291-9. 2006
  10. doi request reprint Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer
    Cosette Marie Wheeler
    Department of Molecular Genetics, House of Prevention Epidemiology, University of New Mexico Health Sciences Center, School of Medicine, 1816 Sigma Chi Road, Building 191, Albuquerque, NM 87106, USA
    Obstet Gynecol Clin North Am 35:519-36; vii. 2008

Research Grants

Detail Information

Publications59

  1. doi request reprint The natural history of cervical human papillomavirus infections and cervical cancer: gaps in knowledge and future horizons
    Cosette Marie Wheeler
    Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Obstet Gynecol Clin North Am 40:165-76. 2013
    ..Promising biomarkers are emerging that may aid in defining which HPV-infected women are at risk of developing invasive cervical cancer...
  2. doi request reprint Cervical histopathology variability among laboratories: a population-based statewide investigation
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services DHHS, Bethesda, MD, USA
    Am J Clin Pathol 139:330-5. 2013
    ..In conclusion, the frequency of diagnoses requiring special staining (p16(INK4a) immunostaining) to adjudicate equivocal CIN2 will be sizable and vary between laboratories, especially if extended to a fraction of CIN1 lesions...
  3. pmc A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination
    Cosette M Wheeler
    Department of Pathology and Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, Albuquerque, NM87131, USA
    Int J Cancer 132:198-207. 2013
    ..e., type replacement)...
  4. doi request reprint Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: r
    Cosette M Wheeler
    Department of Pathology, University of New Mexico, Health Science Center, Albuquerque, NM 87131, USA
    Pediatr Infect Dis J 30:e225-34. 2011
    ..Reactions and immunologic interference with concomitantly administered vaccines are unpredictable, necessitating clinical evaluation...
  5. doi request reprint Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    Cosette M Wheeler
    Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
    Lancet Oncol 13:100-10. 2012
    ....
  6. doi request reprint Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
    Cosette M Wheeler
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center School of Medicine, Albuquerque, NM 87131, USA
    Vaccine 26:686-96. 2008
    ..001) to that of HBV vaccine alone. Overall, co-administered and individual vaccines were generally well-tolerated and did not interfere with the immune response of either vaccine (ClinicalTrials.gov number, NCT00092521)...
  7. ncbi request reprint Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing
    Cosette M Wheeler
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, Building 191, 1816 Sigma Chi Road, Albuquerque, NM 87131, USA
    Nat Clin Pract Oncol 4:224-35. 2007
    ..HPV testing is more sensitive and reproducible than cytology with colposcopy for the detection of cervical precancer and cancer. This article presents current advances and perspectives on HPV vaccines and HPV testing...
  8. ncbi request reprint EUROGIN 2007 roadmap--conclusion
    Cosette M Wheeler
    Department of Molecular Genetics, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, 1816 Sigma Chi Road NE, Albuquerque, NM 87131, USA
    Vaccine 26:A28-31. 2008
  9. ncbi request reprint Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer
    Cosette M Wheeler
    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, School of Medicine, Albuquerque, NM 87131, USA
    J Infect Dis 194:1291-9. 2006
    ..Prospective data on the risks of cervical precancer associated with specific human papillomavirus (HPV) genotypes are limited...
  10. doi request reprint Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer
    Cosette Marie Wheeler
    Department of Molecular Genetics, House of Prevention Epidemiology, University of New Mexico Health Sciences Center, School of Medicine, 1816 Sigma Chi Road, Building 191, Albuquerque, NM 87106, USA
    Obstet Gynecol Clin North Am 35:519-36; vii. 2008
    ....
  11. doi request reprint The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years
    Cosette M Wheeler
    University of New Mexico, Department of Molecular Genetics and Microbiology, Albuquerque, NM 87131, USA
    J Infect Dis 199:936-44. 2009
    ..The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment...
  12. pmc Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States
    Cosette M Wheeler
    House of Prevention Epidemiology, Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico Health Sciences Center, 1816 Sigma Chi Rd Bldg 191, Albuquerque, NM 87131, USA
    J Natl Cancer Inst 101:475-87. 2009
    ..Such studies are needed to predict how HPV vaccination and HPV-based screening will influence cervical cancer prevention...
  13. pmc Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3
    Long Fu Xi
    Department of Pathology, School of Medicine, University of Washington, 1914 North 34th St, Suite 300, Seattle, WA 98103, USA
    J Natl Cancer Inst 101:153-61. 2009
    ..The clinical relevance of the amount of human papillomavirus type 18 (HPV18) DNA in cervical tissue (ie, HPV18 DNA load) is unknown...
  14. pmc Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, School of Medicine, Health Sciences Center, University of New Mexico, Albuquerque, NM 87111, USA
    J Clin Microbiol 44:1755-62. 2006
    ..HPV-16 E2 expressed from intact episomes may act in trans to regulate integrated genome expression of E6 and E7...
  15. ncbi request reprint Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, University of New Mexico, Health Sciences Center, School of Medicine, Albuquerque, NM 87111, USA
    Virology 338:22-34. 2005
    ..Several novel HPV 18 nucleotide variations were identified in this study...
  16. ncbi request reprint Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants
    Long Fu Xi
    Department of Pathology, School of Medicine, University of Washington, Seattle, WA 98103, USA
    J Infect Dis 195:1340-4. 2007
    ..1 (95% confidence interval, 1.1-8.9) was associated with HPV16 non-European, compared with European, variants, a finding that is consistent with the variant-related risk of prevalent/incident high-grade CIN...
  17. pmc Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine
    Rebecca T Emeny
    Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 5276, USA
    J Virol 76:7832-42. 2002
    ..002, respectively). The robust lymphoproliferative responses were specific for HPV-11, since SIs generated against bovine papillomavirus and HPV-16 VLPs were not generally observed and when detected were similar pre- and postimmunization...
  18. ncbi request reprint Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, University of New Mexico, Health Sciences Center, School of Medicine, Albuquerque, New Mexico 87131, USA
    Genes Chromosomes Cancer 40:277-84. 2004
    ..These losses may be a reflection of both an abnormal immune response and a general genome-wide instability resulting from virus persistence...
  19. ncbi request reprint Human papillomavirus type 16 and 18 variants: race-related distribution and persistence
    Long Fu Xi
    Department of Pathology, School of Medicine, University of Washington, Seattle, WA, USA
    J Natl Cancer Inst 98:1045-52. 2006
    ....
  20. ncbi request reprint Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18
    Long Fu Xi
    Department of Pathology, School of Medicine, University of Washington, Seattle, Washington 98103, USA
    Cancer Epidemiol Biomarkers Prev 16:4-10. 2007
    ..Although the variant lineages of human papillomavirus (HPV) types 16 and 18 are well established, their individual associations with high-grade cervical intraepithelial neoplasia (CIN) have not been extensively evaluated...
  21. pmc Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA
    Wim G V Quint
    Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131 5276, USA
    J Clin Microbiol 44:571-9. 2006
    ..The panel sample materials offer a source of renewable and reproducible material that could be used in the future development of international standard reagents for calibration of HPV DNA assays and kits...
  22. ncbi request reprint A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion
    Martyn Plummer
    International Agency for Research on Cancer, Lyon, France
    J Infect Dis 195:1582-9. 2007
    ..Most infections and associated lesions clear spontaneously. It is important to define the determinants and timing of clearance, so that viral persistence can be recognized and managed...
  23. ncbi request reprint Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil
    Lancet Oncol 6:271-8. 2005
    ....
  24. pmc Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 112:637-45. 2008
    ..To examine the predictors of histologic confirmation of high-grade squamous intraepithelial lesion (HSIL) cytology occurring in follow-up of young women originally referred into a trial because of less severe cytology...
  25. pmc A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study
    Patti E Gravitt
    Department of Epidemiology and Molecular Microbiology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 17:1248-54. 2008
    ..We were interested in comparing the performance of Linear Array (LA; Roche Molecular Systems) to Hybrid Capture 2 (hc2; Digene) for the detection of carcinogenic human papillomavirus (HPV) and cervical precancer...
  26. pmc Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5004, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:109-17. 2008
    ..In conclusion, we found LA to be a promising assay for the detection of HPV genotypes and carcinogenic HPV, and it may be clinically useful for the detection of cervical precancer and cancer in women with equivocal cytology...
  27. ncbi request reprint Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, R Prof Antonio Prudente 109, 4th Floor, 01509 010 Sao Paulo, SP, Brazil
    Vaccine 24:5571-83. 2006
    ..Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported...
  28. ncbi request reprint A study of the impact of adding HPV types to cervical cancer screening and triage tests
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:147-50. 2005
    ..The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer...
  29. ncbi request reprint TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer
    Alina Deshpande
    Bioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
    J Infect Dis 191:969-76. 2005
    ..Altered local levels in the cervix may influence an individual's immune response, thereby affecting persistence of human papillomavirus (HPV) 16 infection, a primary etiological factor for cervical cancer...
  30. pmc Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer
    Rongcun Yang
    Department of Pathology, The Johns Hopkins School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    J Virol 79:6741-50. 2005
    ..Tumor progression is associated with genetic instability and L1 mutants. Selection for assembly-deficient L1 mutations suggests the evasion of MyD88-dependent immune control during cervical carcinogenesis...
  31. ncbi request reprint Interlaboratory reliability of Hybrid Capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Am J Clin Pathol 122:238-45. 2004
    ..73); among those with equivocal or abnormal cytologic findings, kappa values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA...
  32. ncbi request reprint Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women
    Kenneth H Fife
    Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
    Vaccine 22:2943-52. 2004
    ..Antibody to HPV11 and 16 was still present at Month 36 in 96.8 and 93.5% of vaccinees, respectively. Both vaccines were well tolerated and were associated with only mild to moderate injection-site reactions...
  33. ncbi request reprint Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology
    Kathleen McIntyre-Seltman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7074, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:1165-70. 2005
    ....
  34. ncbi request reprint Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine
    Darron R Brown
    Department of Medicine, Indiana University School of Medicine, Emerson Hall Room 435, 545 Barnhill Drive, Indianapolis 46022, USA
    Vaccine 22:2936-42. 2004
    ..These results support the institution of larger efficacy trials for HPV L1 VLP vaccines...
  35. ncbi request reprint Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions
    Mark E Sherman
    Department of Health and Human Services, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland 20892 7374, USA
    Cancer Epidemiol Biomarkers Prev 12:1038-44. 2003
    ..These factors severely limit the clinical use of load measurements irrespective of HPV testing methodology...
  36. ncbi request reprint Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892 7234, USA
    J Natl Cancer Inst 97:1066-71. 2005
    ....
  37. ncbi request reprint Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rm 7066, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Infect Dis 186:1169-72. 2002
    ..001). It appears that the natural history of HPV typically includes periods before and after cytologic abnormality, in which HPV DNA is the more sensitive indicator of infection...
  38. ncbi request reprint Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial
    Constance Mao
    Department of Obstetrics and Gynecology and Epidemiology, University of Washington, Seattle, Washington 98104 2499, USA
    Obstet Gynecol 107:18-27. 2006
    ..Whether protection lasts longer than 18 months and, thus, impacts rates of cervical intraepithelial neoplasia (CIN) 2-3 has not yet been established. We present results from an HPV16 L1 VLP vaccine trial through 48 months...
  39. ncbi request reprint A controlled trial of a human papillomavirus type 16 vaccine
    Laura A Koutsky
    Department of Epidemiology, University of Washington, Seattle, USA
    N Engl J Med 347:1645-51. 2002
    ..Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence of HPV-16 infection may provide important public health benefits...
  40. ncbi request reprint A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 7234, USA
    Am J Clin Pathol 124:722-32. 2005
    ..Smaller amounts of material used in PCR could have limited its sensitivity, but our results demonstrate the importance of optimization and standardization of PCR-based assays for clinical applications...
  41. pmc CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression
    Vinay Badal
    Laboratory for DNA Repair and DNA Methylation in Chemical Carcinogenesis, Institute of Molecular Cell Biology, Singapore 117609, Singapore
    J Virol 77:6227-34. 2003
    ....
  42. ncbi request reprint Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays--an update
    Sonia R Pagliusi
    Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Vaccine 24:S3/193-200. 2006
    ..It is hoped that the establishment of International Units and International Standards for HPV antibody and DNA analysis will be pursued with high priority...
  43. ncbi request reprint Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Am J Obstet Gynecol 191:1590-7. 2004
    ....
  44. ncbi request reprint Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix
    Danh Tran-Thanh
    Départements de Microbiologie Infectiologie, Gynécologie Obstétrique et de Pathologie, Centre Hospitalier de l Universite de Montreal, Universite de Montreal, Montreal, Quebec, Canada
    Am J Obstet Gynecol 188:129-34. 2003
    ..In a cross-sectional study, we investigated the role of herpes simplex virus type 2 as a cofactor to human papillomavirus in cervical cancer...
  45. pmc Human papillomavirus genotype specificity of hybrid capture 2
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5030, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    J Clin Microbiol 46:2595-604. 2008
    ..In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported...
  46. ncbi request reprint Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease
    Aimee R Kreimer
    National Cancer Institute, NIH, 6130 Executive Boulevard, Bethesda, MD 20892 7333, USA
    Cancer Epidemiol Biomarkers Prev 15:908-14. 2006
    ....
  47. doi request reprint An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS)
    Philip E Castle
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 111:847-56. 2008
    ....
  48. ncbi request reprint Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    Diane M Harper
    Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Rubin 880, One Medical Center Drive, Lebanon, NH 03756, USA
    Lancet 367:1247-55. 2006
    ....
  49. ncbi request reprint HLA alleles and risk of cervical intraepithelial neoplasia among southwestern American Indian women
    Melissa A Schiff
    Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98104, USA
    Hum Immunol 66:1050-6. 2005
    ..7, 95% CI 0.9-7.3). Additionally, DQA1*0102 was associated with increased risk (OR 4.5, 95% CI 1.3-5.3) and HLA-A*02 with decreased risk (OR 0.4, CI 0.2-0.9). Our findings are discussed along with studies in other populations...
  50. ncbi request reprint Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3
    Aimee R Kreimer
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:11-6. 2007
    ..Data from Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study were used to evaluate HPV persistence and reappearance after LEEP...
  51. ncbi request reprint American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors
    Debbie Saslow
    Cancer Control Science Department, American Cancer Society, Altanta, GA, USA
    CA Cancer J Clin 57:7-28. 2007
    ..They address the use of prophylactic HPV vaccines, including who should be vaccinated and at what age, as well as a summary of policy and implementation issues. Implications for screening are also discussed...
  52. ncbi request reprint Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Int J Cancer 117:1007-12. 2005
    ....
  53. pmc Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines
    Suzanne M Garland
    Microbiology and Infectious Diseases Department, Royal Women s Hospital, Carlton, University of Melbourne, Melbourne, Victoria, Australia
    Clin Vaccine Immunol 14:792-5. 2007
    ....
  54. ncbi request reprint Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    Suzanne M Garland
    Microbiology and Infectious Diseases Department, Royal Women s Hospital, and the University of Melbourne, Melbourne, Australia
    N Engl J Med 356:1928-43. 2007
    ..A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18...
  55. ncbi request reprint Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
    Elmar A Joura
    Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria
    Lancet 369:1693-702. 2007
    ..Our aim was to do a combined analysis of three randomised clinical trials to assess the effect of a prophylactic quadrivalent HPV vaccine on the incidence of these diseases...
  56. ncbi request reprint Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
    Jorma Paavonen
    University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki, Finland
    Lancet 369:2161-70. 2007
    ....
  57. ncbi request reprint Human papillomavirus vaccines: who will pay, who will receive, when to administer?
    Debbie Saslow
    Cancer Control Science Department, American Cancer Society, Atlanta, Georgia 30329, USA
    Ethn Dis 17:S2-8-13. 2007
    ..Even as HPV vaccination for the prevention of cervical cancer is introduced and promoted, it remains critical that women undergo regular screening regardless of whether they have been vaccinated...
  58. pmc Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay
    Leen Jan van Doorn
    Delft Diagnostic Laboratory, Delft, The Netherlands
    J Clin Microbiol 40:979-83. 2002
    ..031). For the remaining genotypes, including HPV types 16 and 18, the results obtained by the two methods were not significantly different. In general, both genotyping methods are highly suitable for clinical and epidemiological studies...
  59. doi request reprint Variation in HLA class I antigen-processing genes and susceptibility to human papillomavirus type 16-associated cervical cancer
    Alina Deshpande
    Decision Applications Division, Los Alamos National Laboratory, Los Alamos, California, USA
    J Infect Dis 197:371-81. 2008
    ..Genetic variation in these genes may affect protein structure and function and, consequently, the ability of an individual to clear HPV infection...

Research Grants2

  1. HPV Outcomes: Prevention Epidemiology and Surveillance (HOPES)
    Cosette Marie Wheeler; Fiscal Year: 2010
    ..Image-based diagnostic standards will be critical to future population evaluations. ..